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cver since its synthesis by Felix Hoffmann in 1897 and
egistration by the Imperial Patent Office in Berlin in 1899,
he list of diseases and disorders for which aspirin was found
o be beneficial continues to grow. Today, about 50,000 tons
f acetylsalicylic acid are produced every year across the
lobe. If this entire output were pressed into 500-mg
ablets, it would amount to 100 billion tablets every year.
Clearly, aspirin has become a widely used, efficacious drug
ith numerous effects and side effects. Such are its pleio-
ropic effects that most physicians would select aspirin as the
uintessential drug for a survival kit. However, these pleio-
ropic and adverse effects are also such that were aspirin
iscovered today, it would probably not pass muster at the
ood and Drug Administration for any indication without a
lack box warning.
See page 975
In this issue of the Journal, Hermida and et al. (1) report
et another rather unexpected pleiotropic effect of aspirin;
amely, antihypertensive activity. The authors showed that
spirin at a dose of 100 mg lowered blood pressure (BP) by
/5 mm Hg when given at bedtime, but not when given in
he morning. The authors, using 48-h ambulatory BP
onitoring, studied more than 300 untreated patients with
rade 1 hypertension, randomly divided into three groups:
) lifestyle modification; 2) lifestyle modification plus aspi-
in in the morning, and; 3) lifestyle modification plus aspirin
t bedtime. Whereas aspirin given on awakening increased
P slightly (2.6/1.6 mm Hg, p  0.002), there was a robust
nd highly significant BP reduction in patients who received
spirin at bedtime, lasting throughout the 24-h period. The
eduction of BP seen with bedtime aspirin was impressive
nd compared favorably with commonly used antihyperten-
ive drug classes. According to the largest meta-analysis ever
one, such an antihypertensive effect could reduce stroke
ortality by more than 30% and ischemic heart disease
ortality by almost 20% (2).
Given that aspirin is a nonsteroidal anti-inflammatory
rug with inhibitory effects on cyclooxygenases (COX),
hese findings are surprising and thought provoking; COX
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
From the Division of Cardiology, St. Luke’s-Roosevelt Hospital, New York, New
ork.nhibition has vasoconstrictive and antinatriuretic effects,
hich are mediated by inhibition of prostaglandin E-2 and
rostacyclin. Nonsteroidal anti-inflammatory drugs and
OX-2 inhibitors have been well documented to elevate BP
nd to possibly increase the risk of heart attack and stroke
3–8). The mechanism that the authors put forward to
xplain the antihypertensive effect of aspirin is based on the
octurnal rise of the activity of the renin-angiotensin-
ldosterone system (RAAS) (9). Because BP falls during the
ight, renal perfusion pressure decreases resulting in a surge
f RAAS activity by as much as 200%. Conceivably, aspirin
iven at bedtime could abolish or at least mitigate this surge
nd concomitantly diminish the nocturnal trough of nitric
xide production (10), thereby providing a mechanism by
hich BP is lowered. We should also remember there is a
ink between inflammation and hypertension (11) and that
he prolonged use of any anti-inflammatory drug is prone to
ffect the cardiovascular system. Thus, aspirin could possibly
ower BP by its anti-inflammatory properties. Finally, aspi-
in could possibly also lower BP by its central nervous (i.e.,
ypothalamic) effect (12). Although all three of these
ypothetical mechanisms appear plausible, they are fraught
ith a common drawback: the half-life of aspirin is merely
5 min; that of salicylate about 3 h. Why would aspirin,
hen given at bedtime, have an effect on BP lasting a whole
4-h period and why would it when given in the same dose
n the morning, if anything, cause an increase in BP?
The potential implications for antihypertensive therapy of
he findings by Hermida et al. (1) are most important. If one
ssumes—and there is some controversy to this—that the
ntihypertensive efficacy of RAAS blockers is at least to
ome extent dependent on the circulating angiotensin levels,
ow-dose aspirin at bedtime will abolish or at least mitigate
he effect of angiotensin-converting enzyme inhibitors or
ngiotensin receptor blockers on BP. Indeed, nonsteroidal
nti-inflammatory drugs and COX-2 inhibitors have been
hown to antagonize the antihypertensive effect of RAAS
lockers but not of calcium antagonists (13,14). Also, in a
eta-analysis of more than 20,000 patients, most of whom
ad congestive heart failure or coronary artery disease, a
mall reduction in benefits of angiotensin-converting en-
yme inhibitors was documented when aspirin was added
15). Thus, when aspirin is taken at bedtime, calcium
ntagonists or possibly diuretics would become more effi-
acious antihypertensive drug classes than RAAS blockers
r beta-blockers. Also, the findings of Hermida et al. (1) do
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September 20, 2005:984–5 Editorial Commentot provide any data on a dose-response curve, if any,
ertaining to aspirin and BP. One would perhaps expect to
ee a U-shaped relationship, because at higher doses the
OX inhibitory effect of aspirin may well abolish its
ntihypertensive effect and lead to an increase in BP.
These and many other questions will have to be clarified
efore low-dose bedtime aspirin can be recommended
outinely for its antihypertensive efficacy. As provocative as
hese findings are, they originate from a single source only.
s such, however thorough, they should be interpreted with
xtreme caution. The present study showing a BP-lowering
ffect of aspirin is somewhat reminiscent of the various small
eports purporting to document that statins had antihyper-
ensive effects. These findings were recently laid to rest by a
horough, large factorial design study showing not a shred of
vidence that atorvastatin, when added to amlodipine, had
ny effect on BP. I wholeheartedly agree with the authors
hat prospective investigation should address whether or not
spirin given at bedtime will be able to provide incremental
ardiovascular protection, particularly in hypertensive
atients.
eprint requests and correspondence:Dr. Franz H. Messerli, St.
uke’s-Roosevelt Hospital Center, 1000 Tenth Avenue, New
ork, New York 10019. E-mail: fmesserli@aol.com.
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